A potential cancer-related immunomodulatory action of Anisakis EVs also emerged with reduction in CEACAM-1 protein (P = 0.01), which mediates angiogenesis, inflammation and innate and adaptive immune responses [61]. Here, CEACAM1 is linked to cancer.